Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.

Abstract:

:Immune checkpoint inhibitors targeting the programmed cell death (PD)-1 receptor have dramatically changed the landscape of metastatic melanoma treatment. Nevertheless, these immuno-modulatory agents have associated side effects, including dermatologic manifestations. To this end, we report a patient with metastatic melanoma that was treated with a PD-1 inhibitor, and subsequently developed inflammation of existing seborrheic keratosis lesions and new verrucous keratoses, a cutaneous side effect that has not been previously reported to our knowledge. The etiology of seborrheic and verrucous keratoses is not well understood, although their physical and histopathologic similarities to chronic viral-derived lesions, such as human papilloma virus, suggest a potential viral association. Chronic viral infections are known to result in T-cell tolerance because of persistent antigen stimulation. PD-1 inhibition is able to reinvigorate exhausted T cells, which are accordingly able to decrease viral load. Thus, the inflammatory reaction, seen in our patient, may be the result of PD-1 inhibition reactivating virally driven T lymphocytes.

journal_name

Melanoma Res

journal_title

Melanoma research

authors

Rambhia PH,Honda K,Arbesman J

doi

10.1097/CMR.0000000000000477

subject

Has Abstract

pub_date

2018-10-01 00:00:00

pages

475-477

issue

5

eissn

0960-8931

issn

1473-5636

journal_volume

28

pub_type

杂志文章
  • The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family.

    abstract::The cell surface glycoprotein MUC18 was originally identified as a progression associated antigen in melanoma. MUC18 is expressed most strongly on metastatic lesions and advanced primary tumours and is only rarely detected in benign lesions. cDNA cloning revealed MUC18 to be a novel member of the immunoglobulin superf...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/00008390-199310000-00006

    authors: Johnson JP,Rothbächer U,Sers C

    更新日期:1993-10-01 00:00:00

  • Primary malignant melanoma of the esophagus.

    abstract::Primary malignant melanoma of the esophagus is an extremely rare, but highly aggressive, tumor. The prognosis for primary malignant melanoma of the esophagus remains dismal in most literatures. We report here a case of primary malignant melanoma of the esophagus that was treated by surgical resection and, additionally...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283307c8a

    authors: Yang X,Qu J,Wang S

    更新日期:2010-02-01 00:00:00

  • Malignant melanoma and pregnancy.

    abstract::The occurrence of cancer in pregnant women is not a common phenomenon and the real incidence of malignant melanoma during this period is unknown. Many authors reported a poor prognosis in pregnant women with melanoma compared with non-pregnant women's tumour. Several retrospective reviews reported a worsened prognosis...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/01.cmr.0000232295.91536.09

    authors: Silipo V,De Simone P,Mariani G,Buccini P,Ferrari A,Catricala C

    更新日期:2006-12-01 00:00:00

  • Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines.

    abstract::Dissemination of uveal melanomas is almost exclusively haematogenous, making angiogenesis of the tumour a prerequisite for the formation of metastases. Uveal melanomas must employ strategies to evade the immune system in order to escape immune surveillance. We therefore determined the expression of the following angio...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199910000-00003

    authors: Ijland SA,Jager MJ,Heijdra BM,Westphal JR,Peek R

    更新日期:1999-10-01 00:00:00

  • Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.

    abstract::One of the principal applications of tumour markers is the early detection of recurrent disease in the follow-up of patients. In the study described here, we compared the usefulness of two serum markers for melanoma, 5-S-cysteinyldopa (5-S-CD) and melanoma inhibitory activity (MIA), in the monitoring of postsurgical m...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200208000-00003

    authors: Matsushita Y,Hatta N,Wakamatsu K,Takehara K,Ito S,Takata M

    更新日期:2002-08-01 00:00:00

  • E-cadherin expression in human melanoma.

    abstract::Loss of expression of E-cadherin, the major cell-cell adhesion receptor on keratinocytes, has been linked to tumour progression in various carcinomas. As E-cadherin has been reported to be expressed in cultured human melanocytes, we questioned whether loss of E-cadherin expression may also be related to melanocytic tu...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199604000-00007

    authors: Danen EH,de Vries TJ,Morandini R,Ghanem GG,Ruiter DJ,van Muijen GN

    更新日期:1996-04-01 00:00:00

  • Protein tyrosine kinases in malignant melanoma.

    abstract::Protein tyrosyl phosphorylation is an essential component in intracellular signalling, with diverse and crucial functions including mediation of cell proliferation, survival, death, differentiation, migration and attachment. It is regulated by the balance between the activities of protein tyrosine kinases (PTKs) and p...

    journal_title:Melanoma research

    pub_type: 杂志文章,评审

    doi:10.1097/00008390-200010000-00001

    authors: Easty DJ,Bennett DC

    更新日期:2000-10-01 00:00:00

  • Utility of 3-year torso computed tomography and head imaging in asymptomatic patients with high-risk melanoma.

    abstract::There is no general consensus regarding the optimal follow-up strategy for patients with melanoma. We sought to determine the utility and cost effectiveness of radiological restaging of patients with stage IIB-IIIC melanoma at the 3-year follow-up time point. A retrospective review of 210 patients diagnosed with stage...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3283471086

    authors: DeRose ER,Pleet A,Wang W,Seery VJ,Lee MY,Renzi S,Sullivan RJ,Atkins MB

    更新日期:2011-08-01 00:00:00

  • Selective incorporation of the prototype melanoma seeker thiourea into nascent melanin: a chemical insight.

    abstract::The mechanism of selective incorporation of thiourea into melanotic melanoma was investigated by model experiments in which the effect of the compound was examined at various stages of melanogenesis in vitro. Up to 50% inhibition of dopachrome formation was observed in the tyrosinase-dopa reaction in the presence of t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199712000-00006

    authors: Palumbo A,Mårs U,De Martino L,d'Ischia M,Napolitano A,Larsson BS,Prota G

    更新日期:1997-12-01 00:00:00

  • Effect of Toremifene in patients with metastatic melanoma: a phase II study of the EORTC Melanoma Cooperative Group.

    abstract::The EORTC Melanoma Cooperative Group conducted a phase II trial (study number 18891) to study the effect of Toremifene in 45 patients with advanced, metastatic melanoma. Male and female patients, median age 61 (range 23-88) years received a mean total dose of 11 g (4.3-62.6) orally for at least 6 weeks. No objective r...

    journal_title:Melanoma research

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Kleeberg UR,Engel E,Bröcker EB,Avril F,Israels P,Weiss J,Kangas L,van Glabbeke M,Lentz MA

    更新日期:1993-04-01 00:00:00

  • MicroRNA miR-125b induces senescence in human melanoma cells.

    abstract::MicroRNAs (miRNAs) are small noncoding RNA molecules involved in gene regulation. Aberrant expression of miRNA has been associated with the development or progression of several diseases, including cancer. In a previous study, we found that the expression of miRNA-125b (miR-125b) was two-fold lower in malignant melano...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e328345333b

    authors: Glud M,Manfé V,Biskup E,Holst L,Dirksen AM,Hastrup N,Nielsen FC,Drzewiecki KT,Gniadecki R

    更新日期:2011-06-01 00:00:00

  • Effects of interferon-alpha, verapamil and dacarbazine in the treatment of advanced malignant melanoma.

    abstract::Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or interferon-alpha (IFNalpha) as single drugs, or in combination, results in a response rate of approximately 15-20%. This study evaluated the activity and toxicity following treatment with a combination of DTIC, IFNalpha2b and verapamil (V...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200302000-00014

    authors: Andersson R,Ake Hofer P,Riklund-Ahlström K,Henriksson R

    更新日期:2003-02-01 00:00:00

  • In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.

    abstract::In metastatic melanoma (MM) immunomodulating agents, such as interleukin-2 (IL-2) and interferon-α (IFN-α), have shown therapeutic benefit as they enhance antitumor immune response. Considering tumor-induced suppression of natural killer (NK) cell activity, it is of interest to study the affect of these cytokines on t...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32833e3286

    authors: Konjević G,Mirjačić Martinović K,Vuletić A,Babović N

    更新日期:2010-12-01 00:00:00

  • Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.

    abstract::BRAF mutations are found in ~50% of metastatic melanomas, most commonly in codon V600. Vemurafenib improves progression-free survival and overall survival in patients with advanced BRAF-mutated melanoma. The results of a descriptive study evaluating vemurafenib in patients with advanced melanoma harbouring BRAF mutati...

    journal_title:Melanoma research

    pub_type: 杂志文章,多中心研究

    doi:10.1097/CMR.0000000000000398

    authors: Hallmeyer S,Gonzalez R,Lawson DH,Cranmer LD,Linette GP,Puzanov I,Taback B,Cowey CL,Ribas A,Daniels GA,Moore T,Gibney GT,Tawbi H,Whitman E,Lee G,Mun Y,Liu S,Hamid O

    更新日期:2017-12-01 00:00:00

  • The effect of delay time between primary melanoma biopsy and sentinel lymph node dissection on sentinel node status, recurrence, and survival.

    abstract::For primary melanoma, there is a delay between the initial skin biopsy and sentinel lymph node dissection, which may cause anxiety for the patient. The consequences of this delay on disease progression are unknown. The goal of this study was to determine whether delay time for sentinel node dissection from the initial...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e32835861f6

    authors: Parrett BM,Accortt NA,Li R,Dosanjh AS,Thummala S,Kullar R,Cleaver JE,Kashani-Sabet M,Leong SP

    更新日期:2012-10-01 00:00:00

  • Successful palliation of stenosing anorectal melanoma by intratumoral injections with natural interferon-beta.

    abstract::Anorectal malignant melanoma is an uncommon tumour. Unlike for cutaneous melanoma, there are few guidelines for its optimal management. In particular, very few palliative treatment strategies have been described for patients with advanced disease. We report on an 80 year old patient with locally advanced anorectal mel...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200208000-00013

    authors: Ulmer A,Metzger S,Fierlbeck G

    更新日期:2002-08-01 00:00:00

  • The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?

    abstract::CD8 T-cell infiltration of metastatic melanoma may be a useful biomarker for prediction of prognosis and response to therapy. The heterogeneous distribution of CD8 T cells within a single tumor, and across different tumors within a single patient, may complicate quantification of infiltration. However, the impact of h...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000330

    authors: Obeid JM,Hu Y,Erdag G,Leick KM,Slingluff CL Jr

    更新日期:2017-06-01 00:00:00

  • Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

    abstract::Ipilimumab, a fully human, recombinant, monoclonal antibody to cytotoxic T-lymphocyte antigen 4 improves overall survival (OS) in previously treated and untreated metastatic melanoma. This retrospective analysis reports data gathered by a questionnaire on the demographics, outcomes, and toxicity of ipilimumab administ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000108

    authors: Berrocal A,Arance A,Lopez Martin JA,Soriano V,Muñoz E,Alonso L,Espinosa E,Lopez Criado P,Valdivia J,Martin Algarra S,Spanish Melanoma Group.

    更新日期:2014-12-01 00:00:00

  • MDM2 SNP309 promoter polymorphism confers risk for hereditary melanoma.

    abstract::The p53 pathway regulates stress response, and variations in p53, MDM2, and MDM4 may predispose an individual to tumor development. The aim of this study was to study the impact of genetic variation on sporadic and hereditary melanoma. We have analyzed a combination of three functionally relevant variants of the p53 p...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000063

    authors: Thunell LK,Bivik C,Wäster P,Fredrikson M,Stjernström A,Synnerstad I,Rosdahl I,Enerbäck C

    更新日期:2014-06-01 00:00:00

  • Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.

    abstract::Prognostic groups defined by lactate dehydrogenase concentration and number of organ sites containing metastases have been reported for patients treated with dabrafenib and trametinib for advanced melanoma. We aimed to validate these prognostic groups for patients treated with vemurafenib and cobimetinib in the coBRIM...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000634

    authors: Sorich MJ,Rowland A,Hopkins AM

    更新日期:2020-06-01 00:00:00

  • Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.

    abstract::Ophthalmological complications constitute a class effect of treatment with BRAF inhibitors. Encorafenib is a new BRAF inhibitor currently being tested in phase 3 clinical trials for advanced or metastatic melanoma as monotherapy or in combination with the MEK-inhibitor binimetinib. In this study, we present a case of ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000505

    authors: Diamantopoulos PT,Stoungioti S,Anastasopoulou A,Papaxoinis G,Gogas H

    更新日期:2018-12-01 00:00:00

  • Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report.

    abstract::Inositol hexaphosphate (IP6) also called phytic acid is a polyphosphorylated carbohydrate naturally found in cereals, nuts, grains, and high-fiber-containing foods. It has been shown to inhibit the growth of many different tumor cell lines both in vitro and in vivo like colon, pancreas, liver, prostate, and even melan...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000577

    authors: Khurana S,Baldeo C,Joseph RW

    更新日期:2019-06-01 00:00:00

  • Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta.

    abstract::Tumor cell invasion through basement membranes and into stromal tissue are key steps for promoting growth and metastasis. Tumor cells express various extracellular-matrix-degrading enzymes such as matrix metalloproteinases (MMPs) to degrade extracellular matrix components to facilitate tumor migration and invasion. Hi...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0b013e3282a660ad

    authors: Iida J,McCarthy JB

    更新日期:2007-08-01 00:00:00

  • Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells.

    abstract::The presence or absence of melanoma cells in human peripheral blood has recently been shown to be associated with disease prognosis, including overall survival. The detection of tyrosinase mRNA-positive circulating melanoma cells by reverse transcription-polymerase chain reaction (RT-PCR) has been limited to dissemina...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200008000-00007

    authors: Schrader AJ,Probst-Kepper M,Grosse J,Kunter U,Schenk F,Franzke A,Atzpodien J,Buer J

    更新日期:2000-08-01 00:00:00

  • Alkylating benzamides with melanoma cytotoxicity.

    abstract::Radioiodinated N-(2-(diethylamino)ethyl)benzamides have recently been discovered as selective agents for melanotic melanoma and are used for scintigraphic imaging in nuclear medicine. Owing to the high binding capacity, benzamide derivatives conjugated with alkylating cytostatics were synthesized and tested for their ...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-200410000-00004

    authors: Wolf M,Bauder-Wüst U,Mohammed A,Schönsiegel F,Mier W,Haberkorn U,Eisenhut M

    更新日期:2004-10-01 00:00:00

  • Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.

    abstract::In this study, we aimed to evaluate the feasibility and efficacy of peptide-pulsed dendritic cell (DC) vaccine in combination with carboplatin and paclitaxel chemotherapy (DCCP) for patients with stage IV melanoma previously treated with dacarbazine-containing regimen. Six HLA-A24 and 3 HLA-A02 patients were treated w...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000342

    authors: Fukuda K,Funakoshi T,Sakurai T,Nakamura Y,Mori M,Tanese K,Tanikawa A,Taguchi J,Fujita T,Okamoto M,Amagai M,Kawakami Y

    更新日期:2017-08-01 00:00:00

  • Relationship between 4-hydroxyanisole toxicity and dopa oxidase activity for three melanoma cell lines.

    abstract::We studied the response of mouse B16F10 and SK-MEL-28 and SK-MEL-1 human melanoma cell lines to treatment with 4-hydroxyanisole (4-HA), and attempted to relate the response to the dopa oxidase levels and the morphological characteristics of each cell line. Clear dose-response curves were observed after 24 h of treatme...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/00008390-199710000-00003

    authors: Rodriguez-Vicente J,Vicente-Ortega V,Canteras-Jordana M,Calderon-Rubiales F

    更新日期:1997-10-01 00:00:00

  • Accessibility to air travel correlates strongly with increasing melanoma incidence.

    abstract::As the cost of air travel has decreased substantially in the USA and Europe over the past few decades, leisure travel to vacation destinations during the winter months has expanded significantly. This trend has probably increased the incidence of significant ultraviolet radiation exposure and sunburn in a broader popu...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/01.cmr.0000195696.50390.23

    authors: Agredano YZ,Chan JL,Kimball RC,Kimball AB

    更新日期:2006-02-01 00:00:00

  • Serum zinc levels are increased in melanoma patients.

    abstract::We studied the levels of serum copper and zinc as possible diagnostic factors or markers for the early detection of patients with melanoma. Levels were determined in 35 melanoma patients at various clinical stages and in 39 healthy persons. Measurements were performed by atomic absorption spectroscopy using 5100-PC-Pe...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:

    authors: Ros-Bullón MR,Sánchez-Pedreño P,Martínez-Liarte JH

    更新日期:1998-06-01 00:00:00

  • Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.

    abstract::Patients with brain metastases (BM) from melanoma have an overall survival (OS) of 2-6 months after whole-brain radiotherapy. Targeted therapy (TT) is an effective treatment for BRAF-mutated metastatic melanoma. Moreover, recent studies indicate intracranial responses of TT in patients with BM. We analyzed 146 patient...

    journal_title:Melanoma research

    pub_type: 杂志文章

    doi:10.1097/CMR.0000000000000429

    authors: Geukes Foppen MH,Boogerd W,Blank CU,van Thienen JV,Haanen JB,Brandsma D

    更新日期:2018-04-01 00:00:00